GAITHERSBURG, Md., Oct. 2, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that it has signed an agreement worth approximately $3.5 million with the Naval Medical Research Center ...

GAITHERSBURG, Md., Sept. 25, 2012 /PRNewswire/ – GenVec, Inc. (NASDAQ:GNVC) announced today that it is lowering its operating costs to conserve capital including eliminating 23 positions, or ...

GenVec Inc.’s president and CEO said Pfizer Inc.’s decision to discontinue co-development of a cardiovascular product is a business call and has nothing to do with whether the late-stage drug works.

GAITHERSBURG, Md., Jan. 20, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, provided an update to investors on recent developments and the company's strategic ...

Ohio Valley Wrestling, run by Al Snow, has acquired a new business partner in Genvec Ventures. “OVW is excited to announce that it has secured a new investment and strategic partnership with Genvec ...

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the ...

(GAITHERSBURG, MARYLAND--USA, 31 March 2004) - GenVec, Inc. (Nasdaq:GNVC), PATH's Malaria Vaccine Initiative (MVI), and the U.S. Naval Medical Research Center (NMRC) today announced a dynamic ...

GenVec (NASDAQ:GNVC) surged in morning trade after announcing a new collaborative deal with animal healthcare company Merial in developing and commercializing technology used to produce foot-and-mouth ...

GenVec, Inc. (NASDAQ: GNVC) today announced that it has formed a collaboration with TheraBiologics to develop cancer therapeutics leveraging both GenVec's proprietary gene delivery platform and ...

Biopharmaceutical firm GenVec Inc. is exploring its options, including a possible sale or merger, the company said in a news release Tuesday. The Gaithersburg-based firm said it has engaged Wells ...

Confusion over complicated clinical trial results for its pancreatic cancer treatment has taken a chunk out of GenVec Inc.’s share price in recent days, according to analysts and the company. The ...